Key Highlights
- In 2026, Aldeyra resubmitted its new drug application for reproxalap, and the FDA accepted it for review under a defined PDUFA timeline.
- The company expanded its option agreement with AbbVie, a validating relationship with a major ophthalmology player.
- Reproxalap's regulatory journey has included a prior complete response letter and a subsequent development plan to address the FDA's concerns.
- The dry-eye-disease market is large and growing, with millions of patients and persistent Demand for new therapies.
Aldeyra Therapeutics (NASDAQ:ALDX) has spent years navigating a winding regulatory path for its dry-eye-disease drug, and the story has reached another pivotal juncture. After earlier setbacks with the FDA, the company resubmitted its application for reproxalap, secured FDA acceptance for review, and expanded a Partnership with AbbVie.
A favorable regulatory decision on reproxalap would be transformative, but the drug's history counsels attention to the risks alongside the optimism.
A Resubmission Back Under FDA Review
Reproxalap, Aldeyra's candidate for dry eye disease, has had a complicated regulatory journey, including a prior complete response letter and a subsequent development plan to address the FDA's concerns. In 2026 the company resubmitted the new drug application, and the FDA accepted it for review, setting up a target action date under a defined PDUFA timeline; Aldeyra also expanded its option agreement with AbbVie, a validating relationship with a major ophthalmology player. Acceptance for review is a meaningful step forward, but the earlier complete response letter and the FDA's evolving requirements are reminders that approval is not assured.
Business and Financial Position
Aldeyra is a clinical-stage biotech whose near-term value is closely tied to reproxalap and the large dry-eye-disease market, where an approved therapy could compete for significant share. The expanded AbbVie option provides potential commercialization support and validation, and it can influence the Economics of any approval. As a development-stage company, Aldeyra funds itself through the capital markets, so cash runway and the terms of the AbbVie arrangement are important considerations.
A Binary FDA Decision Ahead
The dominant catalyst is the FDA decision on the resubmitted reproxalap application, along with any interim regulatory communications. Investors will be monitoring the AbbVie partnership's evolution, cash runway, and the company's commercialization readiness should the drug be approved. Regulatory Risk is paramount given reproxalap's history, and competition in the dry-eye market is significant.
The dry-eye-disease market is large and growing, with millions of patients and persistent demand for new therapies, which is why an approval for reproxalap could be commercially significant and why AbbVie's expanded involvement matters. Balanced against that opportunity is reproxalap's difficult regulatory history, which makes the pending decision genuinely uncertain.






Please wait processing your request...